Developer docs
API playgroundTry for free, no card

Search company profiles

Help Therapeutics

Full company profile

uuid0002a1b

Namestring
Help Therapeutics
Legal namestring
HELP Therapeutics Co. Ltd
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Help Therapeutics is a clinical-stage Chinese biotechnology company developing allogeneic, off-the-shelf cell therapies derived from induced pluripotent stem cells (iPSC) for degenerative diseases, with a primary focus on advanced and end-stage heart failure. Founded in 2016 in Nanjing by Dr. Eugene J. Wang, the company has built a pipeline of iPSC-derived products, including lead candidate HiCM-188 (an intramyocardial injection of iPSC-derived cardiomyocytes, the first iPSC-derived cardiomyocyte therapy to receive IND clearance in both China and the United States), HiCM-388 (acute myocardial infarction), HMM-910 (osteoporosis), and HiO-630 (dry age-related macular degeneration), supported by the Ministry of Science and Technology-authorized iPSC Cell Bank for rare disease research.

The company's core technology platform combines proprietary serum-free, genetic vector-free, integration-free iPSC reprogramming with a self-developed fully automated manufacturing system (Cellfoundry / HELP Cell-foundry) compliant with US and Chinese cGMP standards. The company has demonstrated first-in-human clinical activity in cardiac regeneration, with Nature publishing its 2020 study of iPSC-derived cardiomyocytes for end-stage heart failure and Circulation publishing follow-on mechanism data in 2022. Manufacturing is anchored in Nanjing, with additional offices in Hong Kong, Shenzhen, and Beijing.

Help Therapeutics is pre-revenue and monetizes through a combination of expected direct hospital sales and licensing/co-development partnerships post-approval. Its go-to-market model blends enterprise field sales to major hospital and clinical trial sites with strategic commercialization partnerships, exemplified by the 2025 China Resources Sanjiu co-development and commercialization deal for HiCM-188 in Mainland China, alongside future licensing royalties and milestone payments tied to pipeline assets. Capital is sourced from venture and growth investors led by Juming Venture Capital, with cumulative funding in the hundreds of millions of dollars across multiple rounds from 2019 to 2025.

Short descriptiontext

Help Therapeutics is a clinical-stage Chinese biotech developing allogeneic iPSC-derived cell therapies, with lead asset HiCM-188 (cardiomyocytes for advanced heart failure) in Phase II trials in China and Phase I/II in the US, Singapore, and Thailand.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNanjing, China
HQ citystring
Nanjing
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
iPSC cell therapy, regenerative medicine, cardiomyocyte therapy, heart failure treatment, cell therapy platform
Industry4 codes
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine (Cell Therapy)
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1iPSC Cell Therapy Products
TypeOne Time License
Description

Revenue from sale of allogeneic off-the-shelf iPSC-derived cell therapy products for treatment of degenerative diseases. Lead product HiCM-188 (cardiomyocytes) is in Phase II clinical trials in China and Phase I/II in US, Singapore, and Thailand. Once approved, products will be commercialized through direct hospital sales and partnership channels.

en.helptherapeutics.com
2Co-development and Licensing Revenue
TypeLicensing Royalties
Description

Strategic partnerships for co-development and commercialization of pipeline products generate revenue through milestone payments, development support, and commercialization royalties. Partnership with China Resources Sanjiu for HiCM-188 in Mainland China exemplifies this model.

en.helptherapeutics.com
3iPSC Cell Banking Services
TypeManaged Services
Description

As the officially recognized iPSC rare disease cell repository in China's 14th Five-Year Plan, the company provides high-quality and diverse biological samples to research units and enterprises to accelerate rare disease research and orphan drug development.

en.helptherapeutics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1HiCM-188
Description

iPSC-derived cardiomyocyte injection for treatment of advanced heart failure

en.helptherapeutics.com
+5 more records
Core offering1 text field

Help Therapeutics develops and manufactures allogeneic, off-the-shelf cell therapy products derived from induced pluripotent stem cells (iPSC) targeting degenerative diseases, with a lead product HiCM-188 (iPSC-derived cardiomyocyte injection) for advanced and end-stage heart failure currently in Phase II trials in China and Phase I/II trials in the US, Singapore, and Thailand. The company also operates a government-authorized iPSC biospecimen bank for rare disease research and a fully automated cGMP-compliant cell manufacturing platform (Cellfoundry) supporting its pipeline.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 24-month follow-up data from three patients showed excellent efficacy and safety of iPSC-derived cardiomyocyte drugs for severe heart failure treatment
+3 more records
Product overview1 text field

HELP Therapeutics is a clinical-stage regenerative medicine company developing a unified platform of allogeneic, off-the-shelf iPSC-derived cell therapy products. The core offering centers on HiCM-188, an iPSC-derived cardiomyocyte injection for advanced heart failure currently in Phase II trials in China and Phase I/II trials internationally. Supporting infrastructure includes the iPSC Cell Bank for rare disease research and the Cellfoundry automated manufacturing platform. Additional pipeline candidates (HiCM-388, HMM-910, HiO-630) address acute myocardial infarction, osteoporosis, and dry AMD respectively.

Product and service6 records
1HiCM-188
CategoryCore Cell Therapy Product
Description

Allogeneic, off-the-shelf iPSC-derived cardiomyocyte injection for the treatment of advanced and end-stage heart failure. It is the first and only iPSC-derived cardiomyocyte therapy to receive IND clearance in both China and the United States, intended for hospital-based administration to heart failure patients who have exhausted conventional therapies.

2HiCM-388
CategoryPipeline Cell Therapy Product
Description

Pipeline-stage iPSC-derived cardiomyocyte therapy in development for the treatment of acute myocardial infarction (post-reperfusion) in China.

3HMM-910
CategoryPipeline Cell Therapy Product
Description

Pipeline-stage iPSC-derived cell therapy in development for the treatment of osteoporosis in China.

4HiO-630
CategoryPipeline Cell Therapy Product
Description

Pipeline-stage iPSC-derived cell therapy in development for the treatment of dry age-related macular degeneration (AMD) in China, supported by an iPSC-RPE translational research program approved by Jiangsu provincial and municipal authorities.

5iPSC Cell Bank
CategoryBiospecimen Banking Service
Description

Government-authorized iPSC biospecimen bank — the first authorized by China's Ministry of Science and Technology for human genetic resources conservation and the only officially recognized iPSC rare disease cell repository in China's 14th Five-Year Plan — providing high-quality and diverse biological samples to research units and enterprises for rare disease research and orphan drug development.

6Cellfoundry
CategoryCell Manufacturing Platform
Description

Fully automated cell production and quality control platform compliant with US and China cGMP standards, supporting large-scale, standardized manufacturing of iPSC-derived therapeutic cell products with reduced batch-to-batch variation and lower production costs.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1China Resources Sanjiu
Strategic tierCore/FlagshipTypeStrategic or Co-development PartnerAnnounced on2025-06-16
Description

HELP Therapeutics and China Resources Sanjiu Pharmaceutical Company announced a strategic partnership to co-develop and commercialize HiCM-188 for advanced heart failure in Mainland China. China Resources Sanjiu is one of China's largest pharmaceutical companies. The partnership leverages their exceptional clinical network, innovation mindset, and commercial capabilities to accelerate therapy availability to patients and contribute to the growth of China's cell therapy industry.

en.helptherapeutics.com
2Jiangsu Provincial People's Hospital
Strategic tierModerateTypeStrategic or Co-development PartnerAnnounced on2022-08-08
Description

HELP Therapeutics and Jiangsu Provincial People's Hospital collaborate on iPSC-RPE (retinal pigment epithelial) clinical translational research for age-related macular degeneration (AMD). The project was approved for provincial and municipal projects by Jiangsu Provincial Science and Technology Department and Nanjing Science and Technology Bureau. Prof. Liu Qinghuai and Prof. Yuan Songtao from the hospital are collaborating on this initiative.

en.helptherapeutics.com
Strategic tierModerateTypeStrategic or Co-development PartnerAnnounced on2022-07-21
Description

HELP Therapeutics partnered with Zhuhai University Institute of Science and Technology (representing University of Macau) to build a joint laboratory for regenerative medicine research. Located in Hengqin Guangdong-Macao Deep Cooperation Zone at the Chinese Medicine and Translational Medicine Research and Development Center. The collaboration focuses on degenerative diseases and cell therapy translation, combining HELP Therapeutics' technical advantages with Prof. Chen Guokai's team research capabilities.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Joint laboratory established with Oujiang Laboratory in 2022 as part of the company's expansion of academic-industry research partnerships in regenerative medicine.

5Nanjing Gulou Hospital
Strategic tierCore/FlagshipTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Nanjing Gulou Hospital collaborated with HELP Therapeutics on the world's first human study of iPSC cells for end-stage heart failure (HEAL-CHF clinical trial, NCT03763136). Professor Dongjin Wang serves as Principal Investigator. 24-month follow-up data from three patients showed excellent efficacy and safety. This collaboration produced the Nature-published 2020 landmark study.

en.helptherapeutics.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Japanese clinical-stage biotech developing iPSC-derived cardiomyocytes (HS-001) for heart failure, the most directly comparable iPSC-cardiomyocyte competitor to HiCM-188 in the same indication and modality.

TypeDirect peer
Description

US clinical-stage biotech developing off-the-shelf iPSC-derived cell therapies using a similar reprogramming platform; comparable in modality (allogeneic iPSC) and in early-clinical stage development across multiple indications.

TypeDirect peer
Description

Clinical-stage biotech engineering allogeneic iPSC-derived immune and stem cell therapies; comparable as a next-generation iPSC platform company with multiple pipeline programs at clinical stage.

TypeDirect peer
Description

Bayer-owned clinical-stage biotech developing iPSC-derived engineered cell therapies (including cardiac programs); directly comparable iPSC modality with strong corporate backing and parallel platform ambition.

5Cynata Therapeutics
TypeEmerging player
Description

Australia-based clinical-stage company developing iPSC-derived mesenchymal stem cell therapies, including for cardiovascular indications; overlaps with HELP in iPSC modality and regenerative medicine focus.

TypeDirect peer
Description

Clinical-stage biotech developing cell therapy (CAP-1002, cardiosphere-derived cells) for Duchenne muscular dystrophy-related cardiomyopathy and heart failure; directly comparable cardiac cell therapy focus with later-stage clinical data.

TypeBroad incumbent
Description

Commercial-stage regenerative medicine company with allogeneic cell therapies including Revascor for heart failure; comparable in cardiac cell therapy indication and serves as an indicator of commercial-stage reimbursement dynamics.

8Pluristem Therapeutics
TypeDirect peer
Description

Clinical-stage cell therapy company using placenta-derived adherent stromal cells, including for heart failure (PLX-PAD); comparable in regenerative cell therapy modality and cardiac indication overlap.

TypeBroad incumbent
Description

Large CRO/discovery platform with an iPSC-based drug discovery and cell therapy infrastructure (via alliance partners); comparable as a broader iPSC platform player with industrial-scale cell manufacturing capability.

TypeBroad incumbent
Description

Japanese pharma with a strategic partnership and equity stake in Heartseed for iPSC-derived cardiac cell therapy; comparable as an incumbent investor/commercializer in the iPSC cardiac space and a likely Asia-Pacific commercialization peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Help Therapeutics

Regenerative Medicine (Cell Therapy)en.helptherapeutics.com

Help Therapeutics is a clinical-stage Chinese biotech developing allogeneic iPSC-derived cell therapies, with lead asset HiCM-188 (cardiomyocytes for advanced heart failure) in Phase II trials in China and Phase I/II in the US, Singapore, and Thailand.

What Help Therapeutics does

Help Therapeutics is a clinical-stage Chinese biotechnology company developing allogeneic, off-the-shelf cell therapies derived from induced pluripotent stem cells (iPSC) for degenerative diseases, with a primary focus on advanced and end-stage heart failure. Founded in 2016 in Nanjing by Dr. Eugene J. Wang, the company has built a pipeline of iPSC-derived products, including lead candidate HiCM-188 (an intramyocardial injection of iPSC-derived cardiomyocytes, the first iPSC-derived cardiomyocyte therapy to receive IND clearance in both China and the United States), HiCM-388 (acute myocardial infarction), HMM-910 (osteoporosis), and HiO-630 (dry age-related macular degeneration), supported by the Ministry of Science and Technology-authorized iPSC Cell Bank for rare disease research.

The company's core technology platform combines proprietary serum-free, genetic vector-free, integration-free iPSC reprogramming with a self-developed fully automated manufacturing system (Cellfoundry / HELP Cell-foundry) compliant with US and Chinese cGMP standards. The company has demonstrated first-in-human clinical activity in cardiac regeneration, with Nature publishing its 2020 study of iPSC-derived cardiomyocytes for end-stage heart failure and Circulation publishing follow-on mechanism data in 2022. Manufacturing is anchored in Nanjing, with additional offices in Hong Kong, Shenzhen, and Beijing.

Help Therapeutics is pre-revenue and monetizes through a combination of expected direct hospital sales and licensing/co-development partnerships post-approval. Its go-to-market model blends enterprise field sales to major hospital and clinical trial sites with strategic commercialization partnerships, exemplified by the 2025 China Resources Sanjiu co-development and commercialization deal for HiCM-188 in Mainland China, alongside future licensing royalties and milestone payments tied to pipeline assets. Capital is sourced from venture and growth investors led by Juming Venture Capital, with cumulative funding in the hundreds of millions of dollars across multiple rounds from 2019 to 2025.

Help Therapeutics firmographics

Firmographics
Name
Help Therapeutics
Legal name
HELP Therapeutics Co. Ltd
Website
https://en.helptherapeutics.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Help Therapeutics is a clinical-stage Chinese biotech developing allogeneic iPSC-derived cell therapies, with lead asset HiCM-188 (cardiomyocytes for advanced heart failure) in Phase II trials in China and Phase I/II in the US, Singapore, and Thailand.
Ownership category
akta.pro rank

Help Therapeutics industry classification

Industry
Product category
Regenerative Medicine (Cell Therapy)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • IPSC cell therapy
  • Regenerative medicine
  • Cardiomyocyte therapy
  • Heart failure treatment
  • Cell therapy platform

Where Help Therapeutics is headquartered

Location

Headquarters

HQ city
Nanjing
HQ country
China
HQ region
Asia

Offices4 records

Markets served

Help Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. iPSC Cell Therapy Products: Revenue from sale of allogeneic off-the-shelf iPSC-derived cell therapy products for treatment of degenerative diseases. Lead product HiCM-188 (cardiomyocytes) is in Phase II clinical trials in China and Phase I/II in US, Singapore, and Thailand. Once approved, products will be commercialized through direct hospital sales and partnership channels.
  2. Co-development and Licensing Revenue: Strategic partnerships for co-development and commercialization of pipeline products generate revenue through milestone payments, development support, and commercialization royalties. Partnership with China Resources Sanjiu for HiCM-188 in Mainland China exemplifies this model.
  3. iPSC Cell Banking Services: As the officially recognized iPSC rare disease cell repository in China's 14th Five-Year Plan, the company provides high-quality and diverse biological samples to research units and enterprises to accelerate rare disease research and orphan drug development.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Help Therapeutics product offering

Product offering

Core offering

Help Therapeutics develops and manufactures allogeneic, off-the-shelf cell therapy products derived from induced pluripotent stem cells (iPSC) targeting degenerative diseases, with a lead product HiCM-188 (iPSC-derived cardiomyocyte injection) for advanced and end-stage heart failure currently in Phase II trials in China and Phase I/II trials in the US, Singapore, and Thailand. The company also operates a government-authorized iPSC biospecimen bank for rare disease research and a fully automated cGMP-compliant cell manufacturing platform (Cellfoundry) supporting its pipeline.

Product overview

HELP Therapeutics is a clinical-stage regenerative medicine company developing a unified platform of allogeneic, off-the-shelf iPSC-derived cell therapy products. The core offering centers on HiCM-188, an iPSC-derived cardiomyocyte injection for advanced heart failure currently in Phase II trials in China and Phase I/II trials internationally. Supporting infrastructure includes the iPSC Cell Bank for rare disease research and the Cellfoundry automated manufacturing platform. Additional pipeline candidates (HiCM-388, HMM-910, HiO-630) address acute myocardial infarction, osteoporosis, and dry AMD respectively.

Differentiator

Problem solved

Functional benefit

Brands

  • HiCM-188: iPSC-derived cardiomyocyte injection for treatment of advanced heart failure
  • HiCM-388
  • HMM-910
  • HiO-630
  • Cellfoundry
  • Help Therapeutics Institute

Products and services

  • HiCM-188 Allogeneic, off-the-shelf iPSC-derived cardiomyocyte injection for the treatment of advanced and end-stage heart failure. It is the first and only iPSC-derived cardiomyocyte therapy to receive IND clearance in both China and the United States, intended for hospital-based administration to heart failure patients who have exhausted conventional therapies.
  • HiCM-388 Pipeline-stage iPSC-derived cardiomyocyte therapy in development for the treatment of acute myocardial infarction (post-reperfusion) in China.
  • HMM-910 Pipeline-stage iPSC-derived cell therapy in development for the treatment of osteoporosis in China.
  • HiO-630 Pipeline-stage iPSC-derived cell therapy in development for the treatment of dry age-related macular degeneration (AMD) in China, supported by an iPSC-RPE translational research program approved by Jiangsu provincial and municipal authorities.
  • iPSC Cell Bank Government-authorized iPSC biospecimen bank — the first authorized by China's Ministry of Science and Technology for human genetic resources conservation and the only officially recognized iPSC rare disease cell repository in China's 14th Five-Year Plan — providing high-quality and diverse biological samples to research units and enterprises for rare disease research and orphan drug development.
  • Cellfoundry Fully automated cell production and quality control platform compliant with US and China cGMP standards, supporting large-scale, standardized manufacturing of iPSC-derived therapeutic cell products with reduced batch-to-batch variation and lower production costs.

Quantifiable outcome

  • 24-month follow-up data from three patients showed excellent efficacy and safety of iPSC-derived cardiomyocyte drugs for severe heart failure treatment
  • +3 more outcomes

Companies that use Help Therapeutics

Customer profile

Named customers4 records

Segments1 record

Ideal customer profiles3 records

Help Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Help Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core/flagship, moderate and minor.

  • China Resources Sanjiucore/flagshipStrategic or Co-development Partner · 16 June 2025HELP Therapeutics and China Resources Sanjiu Pharmaceutical Company announced a strategic partnership to co-develop and commercialize HiCM-188 for advanced heart failure in Mainland China. China Resources Sanjiu is one of China's largest pharmaceutical companies. The partnership leverages their exceptional clinical network, innovation mindset, and commercial capabilities to accelerate therapy availability to patients and contribute to the growth of China's cell therapy industry.
  • Jiangsu Provincial People's HospitalmoderateStrategic or Co-development Partner · 8 August 2022HELP Therapeutics and Jiangsu Provincial People's Hospital collaborate on iPSC-RPE (retinal pigment epithelial) clinical translational research for age-related macular degeneration (AMD). The project was approved for provincial and municipal projects by Jiangsu Provincial Science and Technology Department and Nanjing Science and Technology Bureau. Prof. Liu Qinghuai and Prof. Yuan Songtao from the hospital are collaborating on this initiative.
  • University of MacaumoderateStrategic or Co-development Partner · 21 July 2022HELP Therapeutics partnered with Zhuhai University Institute of Science and Technology (representing University of Macau) to build a joint laboratory for regenerative medicine research. Located in Hengqin Guangdong-Macao Deep Cooperation Zone at the Chinese Medicine and Translational Medicine Research and Development Center. The collaboration focuses on degenerative diseases and cell therapy translation, combining HELP Therapeutics' technical advantages with Prof. Chen Guokai's team research capabilities.
  • Oujiang LaboratoryminorStrategic or Co-development Partner · 1 January 2022Joint laboratory established with Oujiang Laboratory in 2022 as part of the company's expansion of academic-industry research partnerships in regenerative medicine.
  • Nanjing Gulou Hospitalcore/flagshipStrategic or Co-development Partner · 1 January 2019Nanjing Gulou Hospital collaborated with HELP Therapeutics on the world's first human study of iPSC cells for end-stage heart failure (HEAL-CHF clinical trial, NCT03763136). Professor Dongjin Wang serves as Principal Investigator. 24-month follow-up data from three patients showed excellent efficacy and safety. This collaboration produced the Nature-published 2020 landmark study.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Help Therapeutics competitors and assessment

Company assessment

Direct peers

  • Heartseed: Japanese clinical-stage biotech developing iPSC-derived cardiomyocytes (HS-001) for heart failure, the most directly comparable iPSC-cardiomyocyte competitor to HiCM-188 in the same indication and modality.
  • Fate Therapeutics: US clinical-stage biotech developing off-the-shelf iPSC-derived cell therapies using a similar reprogramming platform; comparable in modality (allogeneic iPSC) and in early-clinical stage development across multiple indications.
  • Century Therapeutics: Clinical-stage biotech engineering allogeneic iPSC-derived immune and stem cell therapies; comparable as a next-generation iPSC platform company with multiple pipeline programs at clinical stage.
  • BlueRock Therapeutics: Bayer-owned clinical-stage biotech developing iPSC-derived engineered cell therapies (including cardiac programs); directly comparable iPSC modality with strong corporate backing and parallel platform ambition.
  • Capricor Therapeutics: Clinical-stage biotech developing cell therapy (CAP-1002, cardiosphere-derived cells) for Duchenne muscular dystrophy-related cardiomyopathy and heart failure; directly comparable cardiac cell therapy focus with later-stage clinical data.
  • Pluristem Therapeutics: Clinical-stage cell therapy company using placenta-derived adherent stromal cells, including for heart failure (PLX-PAD); comparable in regenerative cell therapy modality and cardiac indication overlap.

Emerging players

  • Cynata Therapeutics: Australia-based clinical-stage company developing iPSC-derived mesenchymal stem cell therapies, including for cardiovascular indications; overlaps with HELP in iPSC modality and regenerative medicine focus.

Broad incumbents

  • Mesoblast: Commercial-stage regenerative medicine company with allogeneic cell therapies including Revascor for heart failure; comparable in cardiac cell therapy indication and serves as an indicator of commercial-stage reimbursement dynamics.
  • Evotec: Large CRO/discovery platform with an iPSC-based drug discovery and cell therapy infrastructure (via alliance partners); comparable as a broader iPSC platform player with industrial-scale cell manufacturing capability.
  • Sumitomo Pharma: Japanese pharma with a strategic partnership and equity stake in Heartseed for iPSC-derived cardiac cell therapy; comparable as an incumbent investor/commercializer in the iPSC cardiac space and a likely Asia-Pacific commercialization peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Help Therapeutics compliance and trust

Trust signal

Compliance3 records

Help Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Help Therapeutics leadership team

Management profile

Number of profiles

Profiles2 records

Help Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Help Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Help Therapeutics

What does Help Therapeutics do?

Help Therapeutics develops and manufactures allogeneic, off-the-shelf cell therapy products derived from induced pluripotent stem cells (iPSC) targeting degenerative diseases, with a lead product HiCM-188 (iPSC-derived cardiomyocyte injection) for advanced and end-stage heart failure currently in Phase II trials in China and Phase I/II trials in the US, Singapore, and Thailand. The company also operates a government-authorized iPSC biospecimen bank for rare disease research and a fully automated cGMP-compliant cell manufacturing platform (Cellfoundry) supporting its pipeline.

Is Help Therapeutics a public or private company?

Help Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Help Therapeutics founded?

Help Therapeutics was founded in 2016. It employs 11 to 50 people.

Where is Help Therapeutics based?

Help Therapeutics is headquartered in Nanjing, China, in the Asia region.

How does Help Therapeutics make money?

Three revenue lines are on record. iPSC Cell Therapy Products are the primary driver. The others are co-development and Licensing Revenue and iPSC Cell Banking Services.

Who are Help Therapeutics's main competitors?

Direct peers on record are Heartseed, Fate Therapeutics, Century Therapeutics, BlueRock Therapeutics, Capricor Therapeutics and Pluristem Therapeutics. Cynata Therapeutics is listed as an emerging player. Broad incumbents are Mesoblast, Evotec and Sumitomo Pharma.

Does Help Therapeutics have an API?

No public API is recorded for Help Therapeutics.

What industry is Help Therapeutics in?

Help Therapeutics's product category is Regenerative Medicine (Cell Therapy). Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireFrom Follower to Force: China's Biotech Sector Enters the Global Clinical MainstreamChina's biotech sector has evolved into a global innovator, driven by increased R&D investment and clinical trial infrastructure that now surpasses the United States in total trials. HELP Therapeutics is advancing its iPSC-derived heart failure therapy, HiCM-188, through multinational Phase I/II and Phase II trials in the U.S., China, Singapore, and Thailand. The company recently partnered with China Resources Sanjiu Pharmaceutical to accelerate the clinical translation and commercialization of this treatment.The Manila TimesHELP Therapeutics and China Resources Sanjiu Announce Strategic Partnership to Co-Develop and Commercialize HiCM-188 for Advanced Heart FailureHELP Therapeutics and China Resources Sanjiu announced a partnership to co-develop and commercialize HiCM-188, an iPSC-derived cell therapy for heart failure. The therapy received IND clearance in China and the U.S. and is in Phase II trials in China and Phase I/II in the U.S., Singapore, and Thailand.PR NewswireHelp Therapeutics gibt IND-Zulassung der ersten universellen, aus iPS-Zellen (induzierte pluripotente Stammzellen) gewonnenen Kardiomyozyten-Therapie für Herzinsuffizienz im Endstadium in China bekannHelp Therapeutics received Investigational New Drug (IND) approval from China's Center for Drug Evaluation (CDE) for HiCM-188, a therapy derived from induced pluripotent stem cells (iPS) intended to treat end-stage heart failure. This regulatory clearance allows the company to initiate clinical trials in China to evaluate the safety and efficacy of the allogeneic cardiomyocyte implantation across various dosages.PR NewswireHelp Therapeutics Announces IND Approval of First Universal iPSC-derived Cardiomyocyte Therapy for End-stage Heart Failure in ChinaHelp Therapeutics Co., Ltd. received Investigational New Drug (IND) approval from China's Center for Drug Evaluation (CDE) for HiCM-188, an allogeneic iPSC-derived cardiomyocyte therapy for end-stage ischemic heart failure, making it the first such therapy approved in China. The therapy uses proprietary serum-free, vector-free, and integration-free conditions to produce purified cardiomyocytes that electrically couple with the patient's myocardium to generate contractile force. Heart failure affects at least 15 million patients in China and approximately 65 million worldwide, and the company plans to advance clinical trials using its automated HELP Cell-foundry platform technology.FinSMEsHelp Therapeutics Completes USD25M Series C FinancingHelp Therapeutics, a Nanjing-based iPSC therapeutics company, raised USD25M in Series C financing led by Ming Bioventures. The funds will support clinical trials of its iPSC heart cell injection and initiate iPSC-based immune cell therapy studies within a year. The company also holds the first iPSC biospecimen bank authorized by China's Ministry of Science and Technology.PR NewswireHelp Therapeutics Completes Series C Financing of 25 Million DollarsHelp Therapeutics, a Chinese iPSC therapeutics platform company, announced the completion of its Series C financing round raising $25 million, led by Ming Bioventures with participation from Share Capital, Beisen Medical Fund, Jolmo Capital, Purple Bull Startups, and financial advisor Hoyue Capital. The financing will fund clinical trials of the company's iPSC heart cell injection product and initiate clinical studies of iPSC-based immune cell therapy within the next year. The company, which obtained China's first iPSC technology-based heart failure cell therapy clinical study filing, positions the product as potentially the first such therapy for moderate to severe heart failure globally.